Top News
Abemaciclib in HR+/HER2– Advanced Breast Cancer Well-Tolerated With Manageable Adverse Effects
Assessing the Impact of Clinical and Pathologic Features on OS in Malignant Peritoneal Mesothelioma
Cardiovascular Risk With Doxorubicin Highlights Need for Early Surveillance
Survival Outcomes in Acute Myeloid Leukemia Associated With Measureable Residual Disease Status
Conventional Chemotherapy May Be Effective in Early-Stage Hodgkin Lymphoma After Relapse
Circulating Tumor Cells May Predict Response to Radium-223 in mCRPC
Clinical Trial: Combination of Letrozole Plus Abemaciclib in Estrogen Receptor–Positive Endometrial Cancer
Clinical Trial: Mirvetuximab Soravtansine and Pembrolizumab in Endometrial Cancer
Risk of Melanoma Measured in Mutation Burden of Skin Cells
Trial to Evaluate PORTEC-4a: Molecular Profile-Based vs Standard Adjuvant Radiotherapy in Endometrial Cancer
Clinical Trial: Phase 3 AtTEnd Trial in Endometrial Cancer
EDITORIAL ADVISORY BOARD
E. David Crawford, MD
Jeffrey M. Farma, MD
Featured
-
Radiation May Be a Useful Bridging Therapy to CAR-T Treatment in Relapsed/Refractory Non-Hodgkin Lymphoma
A new study suggests that radiation prior to CAR-T infusion is a safe bridging therapy — and this approach may even decrease some of the immunotherapy’s side effects, researchers hypothesize. -
Why It’s Been So Hard to Conclusively Link Environmental Factors to Non-Hodgkin Lymphoma
Small studies, the absence of subtypes, and a historical lack of genetic information has stopped past studies from triggering meaningful public health change, a review asserts. -
Comprehensive Genomic Analysis in Some Patients With Breast Cancer Reveals Rare, Pathogenic TP53 Variant in Families of Ashkenazi Jewish Descent
The researchers found 21 early-onset cancer cases carrying the novel pathogenic TP53 variant. -
First-Ever Prospective Trial in Pediatric RCC Reports Results
The prospective study showed that after 4 years, complete resection of the tumor for children with local lymph node involvement (no metastasis) delivered an overall survival rate of 91.4%. -
Tepotinib Yields High Partial Response Rates in NSCLC With MET Alterations
The MET alteration occurs in 3% to 4% of patients with the condition. -
Reliability of Laboratory-Developed Tests Called Into Question
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire. -
Industry-Funded Study Suggests There Is No Association Between TCI Use and Increased Skin Cancer Risk in Atopic Dermatitis
Observational study design and conflicts of interest prevent researchers from determining whether the FDA-mandated black box warning is warranted.
More Features
Research Shows Long-Term Benefit for Adjuvant Targeted Therapies in High-Risk Melanoma
More than half of patients with resected stage 3 melanoma with BRAF V600E or V600K mutations receiving a year’s worth of adjuvant dabrafenib and trametinib were still alive 5 years later.
A Look at DARZALEX® (daratumumab) Treatment Regimen in Newly Diagnosed Multiple Myeloma Patients Who are Transplant Eligible
DARZALEX® is a CD38-directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma.
British Society for Haematology Guideline Update for the Diagnosis and Management of Chronic Myeloid Leukemia
The British Society for Haematology has published updated guidelines for the diagnosis and management of chronic myeloid leukemia in adults and children.
How Do Melanoma Comorbidities Affect Patient Treatment Preferences?
Comorbidities can have an impact on what you as a medical professional think is the best course of treatment for your patients. Can they also affect a patient’s thinking on treatment? Comorbidities such as cardiovascular disease, hypertension, and depression can contribute to how a patient’s body responds to treatment and its attendant stress. A recent…
Maternal, Fetal Considerations for the Treatment and Management of Lymphoma During Pregnancy
Although 1 in 1000 lymphoma diagnoses occurs in pregnancy, literature on best practices for treatment in this patient group is limited.
-
Loading...
-
Loading...
